Package leaflet: Information for the User. Moviprep Orange, powder for oral solution

Similar documents
Package Leaflet: Information for the User

Plenvu powder for oral solution Macrogol 3350, sodium ascorbate, sodium sulfate anhydrous, ascorbic acid, sodium chloride and potassium chloride.

If you need the information on this leaflet in an alternative format, such as large text, or Braille please ring from the UK:

Patient Information Leaflet MOVICOL Paediatric Plain 6.9g sachet, powder for oral solution

Package Leaflet: Information for the user Laxido Paediatric Plain 6.9 g, powder for oral solution

Package Leaflet: Information for the patient. Movicol Ready to Take oral solution in sachet

Package leaflet: Information for the user. Compound Macrogol Oral Powder Sugar Free

Package leaflet: Information for the user

Package leaflet: Information for the user. <PRODUCT NAME> 10 g powder for oral solution in sachet Macrogol 4000

Read all of this leaflet carefully before you start taking this medicine

Package leaflet: Information for the user. Omnilax 10 g powder for oral solution, sachet. Macrogol 4000

MOVIPREP Powder for Solution

Product Information. Powder for Oral Solution. DESCRIPTION: The ingredients of MOVIPREP ORANGE are contained in two separate sachets:

Package leaflet: Information for the patient. Destolit 150 mg tablets Ursodeoxycholic acid

Package Leaflet: Information for the Patient. FOSRENOL 750 mg oral powder. FOSRENOL 1000 mg oral powder. lanthanum

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT. ILAXTEN 20 MG TABLETS bilastine

New Zealand Datasheet. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Sachet A contains the following active ingredients:

PACKAGE LEAFLET: INFORMATION FOR THE USER. XIFAXANTA 200 mg film-coated tablets Rifaximin

PACKAGE LEAFLET: INFORMATION FOR THE USER. Dantrium 25 mg Capsules / Dantrium 100 mg Capsules Dantrolene sodium

Package leaflet: Information for the user

MOVIPREP. Morning Appointment. Information for patients. Endoscopy Unit

PACKAGE LEAFLET: INFORMATION FOR THE USER. SALAGEN 5 mg film-coated tablets. Pilocarpine hydrochloride

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT. Estracyt Capsules Estramustine phosphate 140mg (as estramustine sodium phosphate)

Package leaflet: Information for the user. Cefixime ABR 100 mg/5 ml powder for oral suspension Cefixime

Imodium 1 mg/5 ml oral solution

Package leaflet: Information for the patient. Calcium Folinate 15 mg Tablets calcium folinate

Package leaflet: Information for the user. Fleet Phospho-soda 24.4 g / 10.8 g oral solution

1. What Miacalcic is and what it is used for

Afternoon Appointment - GASTROSCOPY AND COLONOSCOPY

Some general information on hepatitis A infection is given at the end of this leaflet.

Package leaflet: Information for the user. Zonnic Mint 2 mg oromucosal powder in pouch Nicotine

Package leaflet: Information for the patient. Bumetanide 1 mg and 5 mg Tablets (bumetanide)

Package leaflet: Information for the user. GLUCOPHAGE 500 mg powder for oral solution in sachets metformin hydrochloride

PACKAGE LEAFLET: INFORMATION FOR THE USER Nicorandil 10 mg Tablets Nicorandil 20 mg Tablets nicorandil

Package leaflet: Information for the patient

Package leaflet: Information for the user. Ebateva 20 mg Orodispersible Tablets. Ebastine

Package leaflet: Information for the patient. Velphoro 500 mg chewable tablets Iron as sucroferric oxyhydroxide

Package leaflet: Information for the user. Salofalk 3g gastro-resistant prolonged-release granules. Mesalazine

Package Leaflet: Information for the Patient. FOSRENOL 750 mg chewable tablets. FOSRENOL 1000 mg chewable tablets. lanthanum

PACKAGE LEAFLET: INFORMATION FOR THE USER. PEGLAX 10g Powder for oral solution in sachet. Macrogol 4000

Endoscopy Unit MOVIPREP. Afternoon Appointment - GASTROSCOPY AND COLONOSCOPY. Information for patients

Package leaflet: Information for the patient. VEPESID 50 mg and 100 mg capsules, soft Etoposide

Package leaflet: Information for the user. Dalmevin 50 mg tablets Vildagliptin

PACKAGE LEAFLET: INFORMATION FOR THE USER. <PRODUCT NAME> 600 mg / 1,000 IU orodispersible tablets. Calcium/cholecalciferol (Vitamin D3)

Package leaflet: Information for the User Clarityn 1 mg/ml syrup Loratadine

PACKAGE LEAFLET: INFORMATION FOR THE USER AMITIZA 24 MICROGRAM SOFT CAPSULES. Lubiprostone

Package leaflet: Information for the patient. Loratadine 10 mg Tablets (loratadine)

Package leaflet: Information for the user. Resolor 1 mg film-coated tablets Resolor 2 mg film-coated tablets prucalopride

Ventolin Injection 500 micrograms/ml salbutamol sulfate

Package leaflet: Information for the User Clarityn 10 mg tablets Loratadine

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Package leaflet: Information for the user. Elaprase 2 mg/ml concentrate for solution for infusion idursulfase

Package Leaflet: Information for the user. TARGAXAN 550 mg film-coated tablets rifaximin

Package leaflet: Information for the user. Burinex 5 mg Tablets bumetanide

PACKAGE LEAFLET: INFORMATION FOR THE USER

Package leaflet: Information for users. Imodium 2 mg orodispersible tablets Loperamide hydrochloride

PACKAGE LEAFLET: INFORMATION FOR THE USER

Package leaflet: Information for the patient. Zerbaxa 1 g / 0.5 g powder for concentrate for solution for infusion ceftolozane / tazobactam

Package leaflet: Information for the user

Package leaflet: Information for the patient. Moventig 12.5 mg film-coated tablets Moventig 25 mg film-coated tablets. naloxegol

Package Leaflet: Information for the user. Methocarbamol 750mg Film-Coated Tablets

PACKAGE LEAFLET: INFORMATION FOR THE USER. DUKORAL suspension and effervescent granules for oral suspension Cholera vaccine (inactivated, oral)

Package leaflet: Information for the patient. Histaclar 10 mg Film-coated Tablets loratadine

Zinnat can also be used: to treat Lyme disease (an infection spread by parasites called ticks).

Package leaflet: Information for the user Salofalk 500mg gastro-resistant tablets Mesalazine

Package leaflet: Information for the user. Flutamid Stada 250 mg tablets Flutamide

2. What you need to know before you take DDAVP/Desmopressin Tablets

Package leaflet: Information for the patient

PACKAGE LEAFLET: INFORMATION FOR THE USER. Bydureon 2 mg powder and solvent for prolonged-release suspension for injection in pre-filled pen exenatide

Dulcolax 5 mg, film-coated tablets

Package leaflet: Information for the user. SenEase 7.5 mg tablets. Sennosides

PATIENT INFORMATION LEAFLET. Calcichew* 500 mg Chewable Tablets calcium carbonate

1. What Betahistine dihydrochloride tablets is and what it is used for

Package leaflet: Information for the user. Exembol 1 mg/ml solution for infusion. argatroban monohydrate

Package leaflet: Information for the user. Bupivacaine 0.25% w/v, 0.5% w/v solution for injection Bupivacaine Hydrochloride

Package leaflet: Information for the user. Calcichew-D 3 Citron 500 mg/1000 IU chewable tablets calcium/cholecalciferol (vitamin D 3 )

Package Leaflet: Information for the User. Glucosamine sulfate 750 mg Film-Coated Tablets

PACKAGE LEAFLET: INFORMATION FOR THE USER RENNIE DUAL ACTION TABLETS. Calcium carbonate, Magnesium carbonate, Alginic acid Chewable tablets

Ventolin Accuhaler 200 micrograms salbutamol sulfate

Havrix Monodose Vaccine Hepatitis A Vaccine (Inactivated, adsorbed) ELISA Units/1 ml Suspension for Injection in a pre-filled syringe

Package leaflet: Information for the user. Nicovel Frukt 4 mg medicated chewing-gum. nicotine

Package leaflet: Information for the patient. NEGABAN 1g, powder for solution for injection or infusion Temocillin

Package leaflet: Information for the patient. Forxiga 5 mg film-coated tablets Forxiga 10 mg film-coated tablets dapagliflozin

Package leaflet: Information for the patient UNITED KINGDOM Feldene 5mg/g Gel piroxicam

PACKAGE LEAFLET: INFORMATION FOR THE USER. Human Albumin Biotest 20%, solution for infusion Human albumin

Package leaflet: Information for the patient. Vertigon 8 mg Tablets Vertigon 16 mg Tablets (betahistine dihydrochloride)

Irbenida H 150mg/12,5mg film-coated tablets

Zofran syrup contains a medicine called ondansetron. This belongs to a group of medicines called anti-emetics.

Package leaflet: Information for the user. Melatonin Pharma Nord 3 mg, film-coated tablets melatonin

Package leaflet: Information for the patient. Felodipin AstraZeneca 10 mg prolonged-release tablets. felodipine

1 What Zofran Zydis is and what it is used for

Package leaflet: Information for the patient

Package leaflet: Information for the patient

RABEPRAZOL 10mg and 20mg Gastro-resistant Tablets

PATIENT INFORMATION LEAFLET

PACKAGE LEAFLET: INFORMATION FOR THE USER. Variquel 1 mg powder and solvent for solution for injection Terlipressin acetate

Your guide to taking PLENVU

Public Assessment Report

Transcription:

PACKAGE LEAFLET 1

Package leaflet: Information for the User Moviprep Orange, powder for oral solution Macrogol 3350, Sodium sulfate anhydrous, Sodium chloride, Potassium chloride, Ascorbic acid and Sodium ascorbate Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor, or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. If you need the information on this leaflet in an alternative format, such as large text, please ring Medical Information on 01895 826 606. What is in this leaflet 1. What Moviprep Orange is and what it is used for 2. What you need to know before you take Moviprep Orange 3. How to take Moviprep Orange 4. Possible side effects 5. How to store Moviprep Orange 6. Contents of the pack and other information 1. What Moviprep Orange is and what it is used for Moviprep Orange is an orange flavoured laxative contained in four sachets. There are two large sachets ( sachet A ) and two small sachets ( sachet B ). You need all these for one treatment. Moviprep Orange is intended for adults to clean the bowel so that they are ready for examination. Moviprep Orange works by emptying the contents of your bowels, so you should expect to have watery bowel movements. 2. What you need to know before you take Moviprep Orange Do not take take Moviprep Orange if you are allergic (hypersensitive) to the active substances or any of the other ingredients of this medicine (listed in section 6) if you have an obstruction in your intestine (gut) if you have a perforated gut wall if you have a disorder of stomach emptying if you have paralysis of the gut (often occurs after an operation to the abdomen) 2

if you suffer from phenylketonuria. This is a hereditary inability of the body to use a particular amino acid. Moviprep Orange contains a source of phenylalanine if your body is unable to produce enough glucose-6-phosphate dehydrogenase if you have toxic megacolon (a severe complication of acute colitis). Warnings and precautions If you are in poor health or have a serious medical condition, you should be particularly aware of the possible side effects listed in section 4. Contact your doctor or pharmacist if you are concerned. Talk to your doctor or pharmacist before taking Moviprep Orange if you have any of the following: you need to thicken fluids in order to swallow them safely. a tendency to regurgitate swallowed drink, food or acid from the stomach. kidney disease. heart failure or heart disease including high blood pressure, irregular heartbeats or palpitations. thyroid disease dehydration. acute flare of inflammatory bowel disease (Crohn s disease or ulcerative colitis). Moviprep Orange should not be given to patients with impaired consciousness without medical supervision. Children and adolescents should not be taken by children and adolescents aged below 18 years. Other medicines and Moviprep Orange Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. If you are taking other medicines take them at least one hour before taking Moviprep Orange or at least one hour afterwards because they may be flushed through your digestive system and not work so well. Moviprep Orange with food and drink Do not take any solid food from when you start to take Moviprep Orange until after the examination. When taking Moviprep Orange you should continue to take plenty of fluids. The fluid content of Moviprep Orange does not replace your regular liquid intake. Pregnancy, breast-feeding and fertility There are no data on the use of Moviprep Orange during pregnancy or breast-feeding and it should only be used if considered essential by your doctor. If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Driving and using machines Moviprep Orange does not affect your ability to drive or use machines. 3

Moviprep Orange contains sodium, potassium and a source of phenylalanine This medicinal product contains 56.2 mmol of absorbable sodium per litre. To be taken into consideration by patients on a controlled sodium diet. This medicinal product contains 14.2 mmol of potassium per litre. To be taken into consideration by patients with reduced kidney function or patients on a controlled potassium diet. Contains a source of phenylalanine. May be harmful for people with phenylketonuria. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product. 3. How to take Moviprep Orange Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. The recommended dose is two litres of solution, which is made up as follows: This pack contains two clear bags each containing one pair of sachets: sachet A and sachet B. Each pair of sachets (A and B) is to be dissolved in water to make a one litre solution. This pack is therefore sufficient to make up two litres of Moviprep Orange solution. Before you take Moviprep Orange, please read carefully the following instructions. You need to know: When to take Moviprep Orange How to prepare Moviprep Orange How to drink Moviprep Orange What you should expect to happen When to take Moviprep Orange Always take this medicine exactly as described in this leaflet or as your doctor has told you. Check with your doctor if you are not sure. Your treatment with Moviprep Orange must be completed before your examination. This course of treatment can be taken either as divided or single doses as described below: For procedures conducted when you are put to sleep (using general anaesthesia): 1. Divided doses: one litre of Moviprep Orange in the evening before and one litre of Moviprep Orange in the early morning of the day of the examination. Ensure consumption of Moviprep Orange as well as any other clear fluids has finished at least two hours before the start of the examination. 2. Single dose: two litres of Moviprep Orange in the evening before the examination or two litres of Moviprep Orange in the morning of the examination. Ensure consumption of Moviprep Orange as well as any other clear fluids has finished at least two hours before the start of the examination. 4

For procedures conducted without the need for putting you to sleep (without using general anaesthesia): 1. Divided doses: one litre of Moviprep Orange in the evening before and one litre of Moviprep Orange in the early morning of the day of the examination. Ensure consumption of Moviprep Orange as well as any other clear fluids has finished at least one hour before the start of the examination. 2. Single dose: two litres of Moviprep Orange in the evening before the examination or two litres of Moviprep Orange in the morning of the examination. Ensure consumption of Moviprep Orange has finished at least two hours before the start of the examination. Ensure consumption of any clear fluids has finished at least one hour before the examination. Important: Do not take any solid food from when you start to take Moviprep Orange until after the examination. How to prepare Moviprep Orange Open one clear bag and remove the sachets A and B. Add the contents of BOTH sachet A and sachet B to a measuring jug that holds 1 litre. Add water to make up to the one litre mark of the container and stir until all the powder has dissolved and the Moviprep Orange solution is clear or slightly hazy. This may take up to 5 minutes. How to drink Moviprep Orange Drink the first litre of Moviprep Orange solution over one to two hours. Try to drink a glassful every 10-15 minutes. When you are ready, make up and drink the second litre of Moviprep Orange solution made up with the contents of the sachets A and B from the remaining bag. During the course of this treatment, you are recommended to drink a further one litre of clear liquid to prevent you feeling very thirsty and becoming dehydrated. Water, clear soup, fruit juice (without pulp), soft drinks, tea or coffee (without milk) are all suitable. These drinks can be taken at any time you choose. What you should expect to happen When you start drinking the Moviprep Orange solution, it is important that you stay close to a toilet. At some point, you will start to experience watery bowel movements. This is quite normal and indicates that the Moviprep Orange solution is working. The bowel movements will stop soon after you have finished drinking. 5

If you follow these instructions, your bowel will be clear, and this will help you to have a successful examination. You should allow sufficient time after your last drink to travel to the colonoscopy unit. If you take more Moviprep Orange than you should If you take more Moviprep Orange than you should you may develop excessive diarrhoea, which can lead to dehydration. Take generous amounts of fluid, especially fruit juices. If you are worried contact your doctor or pharmacist. If you forget to take Moviprep Orange If you forget to take Moviprep Orange take the dose as soon as you realise you have not taken it. If this is several hours after the time when you should have taken it, contact your doctor or pharmacist for advice. When taking Moviprep Orange as divided doses it is important that you complete your Moviprep Orange preparation at least; one hour before your examination (without use of general anaesthesia), or two hours before your examination (with use of general anaesthesia). When taking all your Moviprep Orange on the morning of the examination as a single dose it is important that you complete your Moviprep Orange preparation at least two hours before your examination. If you have any further questions on the use of this medicine, ask your doctor or pharmacist. 4. Possible side effects Like all medicines can cause side effects, although not everybody gets them. It is normal to get diarrhoea when you take Moviprep Orange. Stop your intake and tell your doctor immediately if you have any of the following side effects: rash or itching swelling of your face, ankles or other part of your body palpitations extreme fatigue shortness of breath These are symptoms of a severe allergic reaction. If you do not have a bowel movement within 6 hours of taking Moviprep Orange, stop the intake and contact your doctor immediately. Other side effects include: Very common side effects (may affect more than 1 in 10 people): Abdominal pain, abdominal distension, tiredness, feeling generally unwell, soreness of the anus, nausea and fever. Common side effects (may affect up to 1 in 10 people): Hunger, problems sleeping, dizziness, headache, vomiting, indigestion, thirst and chills. Uncommon side effects (may affect up to 1 in 100 people): Discomfort, difficulties swallowing, and changes to tests of liver function. 6

The following side effects have sometimes been seen but it is not known how often they occur because the frequency cannot be estimated from the available data: flatulence (wind), temporary increase in blood pressure, irregular heart rhythm or palpitations, dehydration, retching (straining to vomit), very low blood sodium levels that can cause convulsions (fits) and changes to the levels of salts in the blood such as decreased bicarbonate, increased or decreased calcium; increased or decreased chloride and decreased phosphate. Blood potassium and sodium levels could also decrease. These reactions usually only occur for the duration of the treatment. Should they persist, consult your doctor. Allergic reactions may cause a skin rash, itching, reddening of the skin or a nettle rash, swollen hands, feet or ankles, headaches, palpitations and shortness of breath. Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly viayellow Card Scheme Website: www.mhra.gov.uk/yellowcard. By reporting side effects you can help provide more information on the safety of this medicine. 5. How to store Moviprep Orange Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton after EXP. Please note that the expiry dates may be different for the different sachets. The expiry date refers to the last day of the month. Keep Moviprep Orange sachets at room temperature (below 25ºC). After you have dissolved Moviprep Orange in the water, the solution may be stored (keeping covered) at room temperature (below 25 C). It may also be stored in the fridge (2 C -8 C). Do not keep it for more than 24 hours. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. 6. Contents of the pack and other information What Moviprep Orange contains Sachet A contains these active substances Macrogol (also known as polyethylene glycol) 3350 100 g Sodium sulfate anhydrous 7.500 g Sodium chloride 2.691g 7

Potassium chloride 1.015 g Sachet B contains these active substances Ascorbic acid Sodium ascorbate 4.700 g 5.900 g The concentration of electrolyte ions when both sachets are made up to one litre of solution is as follows: Sodium Chloride Sulfate Potassium Ascorbate 181.6 mmol/l (of which not more than 56.2 mmol is absorbable) 59.8 mmol/l 52.8 mmol/l 14.2 mmol/l 29.8 mmol/l The other ingredients are: Orange flavour (containing natural flavouring substances and preparations, maltodextrin, dextrose), aspartame (E951) and acesulfame potassium (E950) as sweeteners. For further information refer to section 2. What Moviprep Orange looks like and contents of the pack This pack contains two clear bags each containing one pair of sachets: sachet A and sachet B. Each pair of sachets (A and B) is to be dissolved in one litre of water. Moviprep Orange powder for oral solution in sachets is available in pack sizes of 1, 10, 40, 80, 160 and 320 packs of a single treatment. Hospital packs of 40 single treatments. Not all pack sizes may be marketed. Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder: Norgine Pharmaceuticals Ltd Norgine House Widewater Place Moorhall Road Harefield Uxbridge Middlesex UB9 6NS Manufacturer: Norgine Limited, New Road, Hengoed, Mid Glamorgan, CF82 8SJ, United Kingdom. The medicinal product is authorised in the Member States of the EEA under the following names: Country Austria Belgium Denmark Tradename MOVIPREP Sinaas/Orange MOVIPREP Appelsin 8

Finland Germany Ireland Italy Luxembourg Netherlands Spain Sweden United Kingdom MOVIPREP Appelsiini MOVIPREP Arancio MOVIPREP Sinaas/Orange MOVIPREP sabor Naranja MOVPREP APELSIN This leaflet was last revised in August 2017 ---------------------------------------------------------------------------------------------------------------------- ------- The following information is intended for healthcare professionals only: Moviprep Orange should be administered with caution to fragile patients in poor health or patients with serious clinical impairment such as: impaired gag reflex, or with a tendency to aspiration or regurgitation impaired consciousness severe renal insufficiency (creatinine clearance <30 ml/min) cardiac impairment (NYHA grade III or IV) those at risk of arrhythmia, for example those on treatment for cardiovascular disease or who have thyroid disease dehydration severe acute inflammatory bowel disease The presence of dehydration or electrolyte shifts should be corrected before the use of Moviprep Orange. Semi-conscious patients or patients prone to aspiration or regurgitation should be closely observed during administration especially if this is via a nasogastric route. Moviprep Orange should not be given to unconscious patients. 9